Protocol Ledger

NCT05304585 · Phase III · RECRUITING

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Interventional Phase III clinical trial protocol NCT05304585 sponsored by Children's Oncology Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-04 Enrollment: 205 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05304585
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)205 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05304585
Protocol FieldVerified Registry Value
NCT IdentifierNCT05304585
Consolidated Lead SponsorChildren's Oncology Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment205 participants (ESTIMATED)
Registered Start Date2022-08-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI